Compass Therapeutics (CMPX) Common Equity (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Common Equity data on file, last reported at $186.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 69.09% year-over-year to $186.5 million; the trailing twelve-month figure through Mar 2026 stood at $186.5 million (up 69.09% YoY), and the FY2025 full-year result was $196.8 million, up 57.14% from the prior year.
• Common Equity declined to $186.5 million in Q1 2026, from $196.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $209.6 million in Q3 2025 to a low of $93.2 million in Q2 2025.
• A 5-year average of $151.4 million and a median of $148.5 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 386.09% in 2022 and tumbled 36.21% in 2025, its largest moves.
• Tracing CMPX's Common Equity over 5 years: stood at $181.6 million in 2022, then slipped by 18.22% to $148.5 million in 2023, then declined by 15.69% to $125.2 million in 2024, then jumped by 57.14% to $196.8 million in 2025, then declined by 5.24% to $186.5 million in 2026.
• Business Quant data shows CMPX's Common Equity at $186.5 million in Q1 2026, $196.8 million in Q4 2025, and $209.6 million in Q3 2025.